NEW YORK (GenomeWeb News) – Magellan Biosciences today announced a deal with Bruker combining their technologies for microbial identification.
Under the terms of the deal, Magellan will develop and test an integrated cross-platform software interface for microbial identification gathered on Bruker's MALDI Biotyper mass spectrometer-based platform combined with results from Magellan's Trek-brand Sensititre susceptibility-testing platform.
Magellan will market and sell the products developed from the deal, the Chelmsford, Mass.-based company said, adding that the products are expected to improve the microbiology laboratory workflow for clinical, research, and veterinary customers.
Magellan did not disclose financial or other terms of the deal.
The MALDI Biotyper has been available in Europe with an IVD-CE mark and is labeled for research-use-only in the US. Bruker plans to seek approval from the US Food and Drug Administration and with regulators in Australia and Canada for the platform.
As a result of the partnership, the MALDI Biotyper's ability to rapidly identify more than 2,000 species of bacteria, yeast and fungi, along with Sensititre's capabilities will create "an expansive list of antimicrobial drugs and dilution ranges, enabling physicians to make more precise dosing decisions," Magellan President and CEO Hiroshi Uchida said in a statement.
Earlier this week, Magellan announced a deal with Miacom Diagnostics to bring that firm's molecular tests to the US and Canada.